In cancer, TIM3 expression is a hallmark of the most exhausted subset of CD8+ T cells, and co-blockade of TIM3 and PD-1 can reactivate suppressed T cells, providing a significant anti-tumor effect in preclinical models [23]. Here, HAVCR2 is linked to neoplasm.